FDA vs EU Whitening Import Compliance: 2026 Checklist

FDA vs EU Whitening Import Compliance: 2026 Checklist for Teeth Whitening Import Compliance Documentation

Sourcing professional whitening products for the U.S. or EU market requires two separate compliance architectures — not one adapted to two destinations. Teeth whitening import compliance documentation is built differently for each jurisdiction because the underlying regulatory classification differs at the foundation. The FDA treats peroxide-based whitening products as OTC drugs. The EU treats them as cosmetics. Every document you need, every concentration limit you must respect, and every liability you carry as importer of record flows from that single classification split.

A shipment that clears EU customs without incident can be detained at a U.S. port of entry for missing drug establishment registration. A formulation that satisfies FDA monograph conditions may exceed EU hydrogen peroxide concentration thresholds and require professional-use supply chain controls. Treating these markets as variations of the same exercise is the most reliable way to generate costly delays, refused entry, or product destruction at your expense.

FDA OTC Monograph M020: The Hard Compliance Boundary for U.S. Importers

The FDA governs hydrogen peroxide-based tooth whitening products under the OTC Drug Monograph system. Monograph M020 — the operative framework for oral care antiseptic and whitening actives — defines which active ingredients are permitted, at what concentrations, and under what labeling conditions a product may enter U.S. commerce without a new drug application.

Products that fall outside monograph conditions are treated as unapproved new drugs. They are subject to refusal of admission at the port of entry. There is no gray zone between monograph-compliant and unapproved — the classification is binary.

Core formulation requirements under the OTC monograph framework:

• Active ingredient identity: The specific peroxide compound must be declared and must appear on the monograph's approved active ingredient list.
• Concentration compliance: The labeled concentration must match the permitted range. Overage claims and underage actives both create regulatory exposure.
• Drug Facts panel: Mandatory format under 21 CFR Part 201. Directions, warnings, and inactive ingredient disclosure must conform precisely.
• Establishment registration: The foreign manufacturer must hold a valid FDA drug establishment registration under 21 CFR Part 207 before any product is imported.
• Drug listing: Each individual SKU must carry a separate drug listing number on file with the FDA.

PAP (phthalimidoperoxycaproic acid) formulations require separate analysis. PAP is not currently listed as an approved active under the OTC monograph for tooth whitening. A PAP-only product may be positioned as a cosmetic in the U.S. — but only if no drug claims appear anywhere on the label or in associated marketing. Any efficacy language referencing whitening or stain removal on a PAP-based product requires qualified legal review before U.S. market entry.

EU CPNP Registration and Teeth Whitening Import Compliance Documentation: Concentration Tiers, Responsible Person Rules, Post-Brexit Changes

In the EU, tooth whitening products are regulated under the EU Cosmetics Regulation (EC) No 1223/2009. Hydrogen peroxide is permitted in oral hygiene and tooth whitening products, but concentration limits are tiered and linked directly to who can supply the product and under what distribution conditions.

The regulation permits hydrogen peroxide up to a defined threshold for general consumer sale. Concentrations above that threshold are restricted to professional dental use — meaning the product may only be supplied through a registered dental practitioner for the initial application cycle. Importers distributing above the consumer threshold must ensure their supply chain, labeling, and end-customer documentation all reflect the professional-use restriction. Selling above the consumer limit through non-dental retail channels is a regulatory violation, not an ambiguous interpretation.

CPNP (Cosmetic Products Notification Portal) registration is mandatory before any cosmetic product is placed on the EU market. The notification must be filed by or on behalf of the Responsible Person — the EU-established legal entity that accepts full liability for the product's compliance with the Cosmetics Regulation. Non-EU manufacturers must appoint an EU-established Responsible Person before any import shipment is dispatched.

Post-Brexit, this rule carries a specific operational consequence. A UK-based Responsible Person no longer satisfies the EU requirement. If your supply chain previously designated a UK entity as the RP for EU distribution, that arrangement is invalid. A separately appointed Responsible Person established within an EU member state is required. The reverse also applies: EU market CPNP notifications do not carry over to the UK's own notification system (SCPN), which now operates independently.

CPNP submission requires a completed Product Information File (PIF) containing:

• Full product description and formula with all ingredients at declared concentrations
• Cosmetic Safety Assessment (CSA) signed by a qualified safety assessor
• Manufacturing method and GMP compliance statement
• Evidence of claimed effects where applicable
• Preservative efficacy data and stability testing results

The Documentation Your Customs Broker Cannot Generate

A customs broker manages tariff classifications and entry filings. What they cannot produce is the product-specific compliance documentation that regulators require at the point of import. That documentation originates with you and your supplier. Its absence is the most common cause of shipment holds for professional whitening products.

For FDA-regulated OTC drug imports, the core documentation set includes:

1. FDA drug establishment registration number for the foreign manufacturer
2. Drug listing number for each SKU being imported
3. Certificate of Analysis (CoA) from a qualified laboratory confirming active ingredient identity and concentration
4. Labeling package conforming to Drug Facts panel requirements under 21 CFR Part 201
5. GMP compliance documentation from the manufacturing site under 21 CFR Parts 210 and 211

For EU cosmetic imports, the documentation maps differently:

1. CPNP notification reference number for each product SKU
2. Responsible Person appointment letter and EU contact details
3. Product Information File held by the RP and available to competent authorities on request
4. Cosmetic Safety Assessment signed by a qualified EU assessor
5. Labeling in the official language(s) of every destination member state

When launching a private-label whitening line — for example, a co-developed gel system for a dental clinic network or a branded whitening strip program for a premium pharmacy chain — both document sets must be completed before the first shipment. Attempting to retrofit compliance documentation onto an already-shipped product is slow, expensive, and sometimes impossible if the manufacturer cannot produce retrospective GMP batch records.

GMP Requirements: What FDA 21 CFR 210/211 and ISO 22716 Actually Demand From Your Supplier

GMP compliance is not a certificate. It is a documented manufacturing system. The distinction matters when evaluating whether a supplier's GMP claim covers your specific product category and your target market.

For FDA OTC drug products, the applicable GMP standard is 21 CFR Parts 210 and 211 — Current Good Manufacturing Practice for finished pharmaceuticals. This standard is materially more demanding than cosmetic GMP. It requires complete batch records, in-process testing protocols, validated cleaning procedures, documented stability programs, and a quality control unit independent of production. Foreign manufacturers exporting OTC drugs to the U.S. are subject to FDA inspection. A supplier holding only ISO 22716 cosmetic GMP certification is not automatically qualified for OTC drug export to the U.S.

For EU cosmetic products, ISO 22716 is the recognized GMP standard referenced under the Cosmetics Regulation. It covers personnel, premises, equipment, raw materials, production, finished product controls, quality control procedures, and waste management. An ISO 22716 audit certificate from an accredited third-party body is the standard form of evidence a Responsible Person will require from any manufacturing partner.

When evaluating a supplier specifically for teeth whitening import compliance documentation purposes, request:

• The most recent full GMP audit report — not only the summary certificate
• Batch record examples, redacted for confidentiality where required
• Stability data specific to the formulation and packaging combination you intend to import
• Raw material supplier qualification records for the active ingredient

Pre-Shipment Compliance Checklist: FDA OTC vs EU CPNP

Use this checklist before authorizing any shipment of professional whitening product into the U.S. or EU markets.

Compliance Item	U.S. (FDA OTC)	EU (CPNP)
Manufacturer FDA drug establishment registration confirmed	Required	Not applicable
Drug listing number on file for each SKU	Required	Not applicable
CPNP notification filed, reference number obtained	Not applicable	Required
EU Responsible Person appointed (EU-established entity)	Not applicable	Required
Certificate of Analysis confirming active ingredient and concentration	Required	Required
GMP documentation (21 CFR 210/211 or ISO 22716 as applicable)	Required	Required
Drug Facts panel labeling reviewed against 21 CFR Part 201	Required	Not applicable
Labeling in destination member state language(s)	Not applicable	Required
Cosmetic Safety Assessment signed by qualified assessor	Not applicable	Required
Professional-use supply chain controls (if above consumer H₂O₂ threshold)	Not applicable	Required where applicable
Stability data for formulation and packaging combination	Required	Required
Post-Brexit: separate UK SCPN notification if distributing in Great Britain	Not applicable	Required where applicable

Red Flags That Signal a Supplier Is Not Ready for Regulated Market Export

Not every manufacturer capable of producing a whitening product can support a compliant import into the U.S. or EU. These indicators should stop a sourcing decision before it becomes a regulatory enforcement problem.

No FDA drug establishment registration number. For OTC drug products destined for the U.S., this is non-negotiable. A supplier without active registration cannot legally export OTC drugs to the United States. No workaround exists at the port of entry.

GMP certification is cosmetic-only, but the product is positioned as an OTC drug. ISO 22716 does not satisfy 21 CFR Parts 210 and 211. A supplier presenting a cosmetic GMP certificate for a product that will be imported and marketed as an OTC drug in the U.S. is not compliant — regardless of what their commercial documentation states.

They cannot produce a signed Cosmetic Safety Assessment. In the EU, a CSA signed by a qualified assessor is a legal prerequisite for CPNP notification. A supplier that cannot support this step cannot place a compliant product on the EU market.

Stability data covers only the formulation, not the finished packaging combination. Stability is packaging-dependent. Gel behavior in a syringe differs from gel behavior in a strip delivery system. Data that does not match your specific delivery format does not satisfy either the FDA or EU documentation requirement.

They reference a UK Responsible Person for EU distribution. Post-Brexit, this arrangement does not satisfy the EU Cosmetics Regulation. If a supplier is presenting pre-2021 compliance infrastructure as current, their understanding of the regulatory landscape is out of date.

For professional buyers building private-label whitening programs engineered for dental clinic networks, premium pharmacy distribution, or branded wellness lines, compliance infrastructure is part of the product — not an afterthought. Explore WhiteningBright's private-label ready whitening portfolio to see how co-developed formulations are supported with full regulatory documentation from the outset.

References

The authoritative sources available for this topic within the verified research set are limited to the FDA regulatory guidance below. No peer-reviewed PubMed studies, ADA clinical publications, or additional government regulatory documents meeting the source criteria specified for this article were confirmed available in the research set provided. Additional citations will be added as qualifying sources are verified.

• U.S. Food and Drug Administration — Importing Cosmetics (FDA Industry Guidance)
• U.S. Food and Drug Administration — Current Good Manufacturing Practice (CGMP) Regulations, 21 CFR Parts 210 and 211
• U.S. Food and Drug Administration — Drug Establishment Registration and Drug Listing

Disclaimer

This article is for general informational purposes only and does not constitute sourcing, legal, or regulatory advice. Always conduct your own due diligence and consult qualified legal or compliance professionals before making purchasing or compliance decisions. WhiteningBright makes no warranties as to the completeness or accuracy of the information, and any reliance is at your own risk.